{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+Phosphate&page=2",
    "query": {
      "intervention": "Sitagliptin Phosphate",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 177,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+Phosphate&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+Phosphate&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T18:06:08.211Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01169090",
      "title": "A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "SK-0403",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kowa Research Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 620,
      "start_date": "2010-07",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2011-08-17",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169090"
    },
    {
      "nct_id": "NCT01106690",
      "title": "The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 344,
      "start_date": "2010-06",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-07-15",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 41,
      "location_summary": "Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burlingame",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01106690"
    },
    {
      "nct_id": "NCT05220917",
      "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Events",
        "Type2 Diabetes",
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "2nd generation SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 781430,
      "start_date": "2021-08-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220917"
    },
    {
      "nct_id": "NCT01741103",
      "title": "Sitagliptin in Type I Diabetic Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Type I"
      ],
      "interventions": [
        {
          "name": "sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-06",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2022-03-24",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Williamsville, New York",
      "locations": [
        {
          "city": "Williamsville",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01741103"
    },
    {
      "nct_id": "NCT01104532",
      "title": "A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Pharmacokinetics of ASP1941"
      ],
      "interventions": [
        {
          "name": "ASP1941",
          "type": "DRUG"
        },
        {
          "name": "sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2010-02",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2010-04-16",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01104532"
    },
    {
      "nct_id": "NCT00616811",
      "title": "Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "vildagliptin",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 148,
      "start_date": "2008-01",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2020-12-17",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 79,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00616811"
    },
    {
      "nct_id": "NCT02639637",
      "title": "Effect of DPP4 Inhibition on Vasoconstriction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Neuropeptide Y",
          "type": "DRUG"
        },
        {
          "name": "Enalaprilat",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2018-08-27",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02639637"
    },
    {
      "nct_id": "NCT02048904",
      "title": "Use of Sitagliptin to Decrease Microalbuminuria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Microalbuminuria"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 142,
      "start_date": "2014-01",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-10",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048904"
    },
    {
      "nct_id": "NCT03101930",
      "title": "Cardiovascular Effects of GLP-1 Receptor Activation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity",
        "PreDiabetes"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "hypocaloric diet",
          "type": "OTHER"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Exendin (9-39)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 329,
      "start_date": "2017-05-01",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03101930"
    },
    {
      "nct_id": "NCT06263673",
      "title": "Anti-Diabetic Medications to Fight PD and LBD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lewy Body Dementia",
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "45 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-05-07",
      "completion_date": "2025-01-08",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-10-05T18:06:08.211Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06263673"
    }
  ]
}